STAT

Opinion: A road map for including Latinos and African Americans in Alzheimer’s research

Small gains are being made across the country to narrow disparities in the diagnosis and treatment of Alzheimer's disease among African Americans and Latinos. But much more needs to be…

Alzheimer’s disease is the only leading cause of death in the U.S. that is still on the rise and that does not have a current effective treatment or cure. The limited inclusion of Latinos and African Americans in research will only worsen the outlook, though the success of efforts bubbling up across the country could help us keep up with the disease.

The face of Alzheimer’s is changing, largely because the No. 1 risk factor for it is advanced age. By 2030, the number of Latinos age 65 and the number of African Americans will have , compared to 65% among non-Hispanic whites. As Sen. Amy Klobuchar (D-Minn.) , by 2030 Latinos and African Americans will make up nearly 40% of the 8.4 million Americans living with Alzheimer’s.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks